305 related articles for article (PubMed ID: 17402321)
1. Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial.
Melman A; Bar-Chama N; McCullough A; Davies K; Christ G
Isr Med Assoc J; 2007 Mar; 9(3):143-6. PubMed ID: 17402321
[TBL] [Abstract][Full Text] [Related]
2. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial.
Melman A; Bar-Chama N; McCullough A; Davies K; Christ G
Hum Gene Ther; 2006 Dec; 17(12):1165-76. PubMed ID: 17134370
[TBL] [Abstract][Full Text] [Related]
3. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results.
Melman A; Bar-Chama N; McCullough A; Davies K; Christ G
Eur Urol; 2005 Aug; 48(2):314-8. PubMed ID: 15964135
[TBL] [Abstract][Full Text] [Related]
4. Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat.
Melman A; Biggs G; Davies K; Zhao W; Tar MT; Christ GJ
Gene Ther; 2008 Mar; 15(5):364-70. PubMed ID: 18200069
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for male erectile dysfunction.
Melman A
Urol Clin North Am; 2007 Nov; 34(4):619-30, viii. PubMed ID: 17983901
[TBL] [Abstract][Full Text] [Related]
6. Gene transfer of the K(ATP) channel restores age-related erectile dysfunction in rats.
So I; Chae MR; Lee SW
BJU Int; 2007 Nov; 100(5):1154-60. PubMed ID: 17645416
[TBL] [Abstract][Full Text] [Related]
7. Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro.
Spektor M; Rodriguez R; Rosenbaum RS; Wang HZ; Melman A; Christ GJ
J Urol; 2002 Jun; 167(6):2628-35. PubMed ID: 11992099
[TBL] [Abstract][Full Text] [Related]
8. Gene transfer for the therapy of erectile dysfunction: progress in the 21st century.
Melman A
Int J Impot Res; 2006; 18(1):19-25. PubMed ID: 16281045
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction.
Buvat J; Hatzichristou D; Maggi M; Farmer I; Martínez-Jabaloyas JM; Miller PJ; Schnetzler G
BJU Int; 2008 Dec; 102(11):1645-50. PubMed ID: 18710446
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
11. 4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction.
Hewawasam P; Fan W; Ding M; Flint K; Cook D; Goggins GD; Myers RA; Gribkoff VK; Boissard CG; Dworetzky SI; Starrett JE; Lodge NJ
J Med Chem; 2003 Jul; 46(14):2819-22. PubMed ID: 12825925
[TBL] [Abstract][Full Text] [Related]
12. [Functional electromyostimulation of the penile corpus cavernosum (FEMCC)]. Initial results of a new therapeutic option of erectile dysfunction].
Stief CG; Weller E; Noack T; Djamilian MH; Meschi M; Truss M; Jonas U
Urologe A; 1996 Jul; 35(4):321-5. PubMed ID: 8928362
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologists?
Melman A; Rojas L; Christ G
Curr Opin Urol; 2009 Nov; 19(6):595-600. PubMed ID: 19741539
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial.
Paick JS; Choi HK; Kim SC; Ahn TY; Kim JJ; Park JK; Park KS; Lee SW; Kim SW; Park K; Jung H; Park NC
Asian J Androl; 2008 Sep; 10(5):791-8. PubMed ID: 18645683
[TBL] [Abstract][Full Text] [Related]
16. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
Bratus D; Hlebic G; Hajdinjak T
Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: Smooth-muscle-specific gene transfer with the human maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys.
Hatzimouratidis K
Eur Urol; 2009 Dec; 56(6):1066. PubMed ID: 19167151
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction.
Tan HM; Chin CM; Chua CB; Gatchalian E; Kongkanand A; Moh CL; Ng FC; Ratana-Olarn K; Serrano D; Taher A; Tambi I; Tantiwong A; Chen MW; Yip WC
Asian J Androl; 2008 May; 10(3):495-502. PubMed ID: 18385912
[TBL] [Abstract][Full Text] [Related]
19. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients.
Padma-Nathan H; Yeager JL
Urology; 2006 Aug; 68(2):386-91. PubMed ID: 16904458
[TBL] [Abstract][Full Text] [Related]
20. Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys.
Christ GJ; Andersson KE; Williams K; Zhao W; D'Agostino R; Kaplan J; Aboushwareb T; Yoo J; Calenda G; Davies KP; Sellers RS; Melman A
Eur Urol; 2009 Dec; 56(6):1055-66. PubMed ID: 19167152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
